Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2506.00673

DuAL-Net: A Hybrid Framework for Alzheimer's Disease Prediction from Whole-Genome Sequencing via Local SNP Windows and Global Annotations

Eun Hye Lee·Taeho Jo
View original source ↗Read source document ↗Export metadata ↓

Abstract

Alzheimer's disease (AD) dementia is the most common form of dementia. With the emergence of disease-modifying therapies, predicting disease risk before symptom onset has become critical. We introduce DuAL-Net, a hybrid deep learning framework for AD dementia prediction using whole genome sequencing (WGS) data. DuAL-Net integrates two components: local probability modeling, which segments the genome into non-overlapping windows, and global annotation-based modeling, which annotates SNPs and reorganizes WGS input to capture long-range functional relationships. Both employ out-of-fold stacking with TabNet and Random Forest classifiers. Final predictions combine local and global probabilities using an optimized weighting parameter alpha. We analyzed WGS data from 1,050 individuals (443 cognitively normal, 607 AD dementia) using five-fold cross-validation. DuAL-Net achieved an AUC of 0.671 using top-ranked SNPs, representing 35.0% and 20.3% higher performance than bottom-ranked and randomly selected SNPs, respectively. ROC analysis demonstrated strong positive correlation between SNP prioritization rank and predictive power. The model identified known AD-associated SNPs as top contributors alongside potentially novel variants. DuAL-Net presents a promising framework improving both predictive accuracy and biological interpretability. The framework and web implementation offer an accessible platform for broader research applications.

Explore related subjects

q-bio.GN

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eun Hye Lee, Taeho Jo. 2025-05-31. DuAL-Net: A Hybrid Framework for Alzheimer's Disease Prediction from Whole-Genome Sequencing via Local SNP Windows and Global Annotations. https://arxiv.org/abs/2506.00673

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Revolutionizing Genomics with Reinforcement Learning Techniques

In recent years, Reinforcement Learning (RL) has emerged as a powerful tool for solving a wide range of problems, including decision-making and genomics. The exponential growth of raw genomic data over the past two decades has exceeded the capacity of manual analysis, leading to a growing interest in automatic data analysis and processing. RL algorithms are capable of learning from experience with minimal human supervision, making them well-suited for genomic data analysis and interpretation. One of the key benefits of using RL is the reduced cost associated with collecting labeled training data, which is required for supervised learning. While there have been numerous studies examining the applications of Machine Learning (ML) in genomics, this survey focuses exclusively on the use of RL in various genomics research fields, including gene regulatory networks (GRNs), genome assembly, and sequence alignment. We present a comprehensive technical overview of existing studies on the application of RL in genomics, highlighting the strengths and limitations of these approaches. We then discuss potential research directions that are worthy of future exploration, including the development of more sophisticated reward functions as RL heavily depends on the accuracy of the reward function, the integration of RL with other machine learning techniques, and the application of RL to new and emerging areas in genomics research. Finally, we present our findings and conclude by summarizing the current state of the field and the future outlook for RL in genomics.

q-bio.GN↗
arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗
arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗